Navigation Links
PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
Date:9/30/2008

Panacea Biotec to Make a $13.1 Million Strategic Investment in PharmAthene

ANNAPOLIS, Md., Sept. 30 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it has entered into a strategic alliance with Panacea Biotec Ltd., that includes a strategic equity investment in PharmAthene by Panacea Biotec, through its subsidiary, Kelisia Holdings Ltd., of $13.1 million in exchange for the sale of common stock and warrants.

Under the financing, Panacea Biotec's subsidiary has agreed to purchase approximately 3.73 million shares of PharmAthene common stock at a negotiated price of $3.50 per share, which represents a 90% premium above the closing price of PharmAthene's common stock on September 29, 2008. Upon the closing, Panacea Biotec's subsidiary will also receive 12-month warrants to purchase up to approximately 2.75 million additional shares of PharmAthene common stock at an exercise price of $5.10 per share. The transaction is expected to close on or before October 20, 2008.

"Our agreement with Panacea Biotec is part of a comprehensive strategy to strengthen our balance sheet and forge a strategic alliance with a globally recognized biopharmaceutical company," said David P. Wright, President and Chief Executive Officer of PharmAthene. "We were attracted to Panacea Biotec because it has distinguished itself as an international health management company that is actively conducting research and development of novel chemical and biological pharmaceutical formulations and has developed a diverse proprietary product portfolio encompassing pediatric vaccines and therapeutics for emerging infectious diseases and othe
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... Increasing its efforts to resolve the GMO Controversy , ... The GMO TRUTH podcast on both ITunes and at The ... mission to discover the truth and change the world. ... truth about the GMOs in our food supply,” adds a ... an expansion of the documentary/investigative film-making methodology in place at ...
(Date:2/27/2015)...  Pharmacyclics, Inc. (NASDAQ: PCYC ) ... newly developed Bruton,s tyrosine kinase (BTK) inhibitor for ... results of these preclinical evaluations have been communicated ... feedback received from the Agency is supportive of ... preclinical work is required to begin a Phase ...
(Date:2/27/2015)... Scotia (PRWEB) February 27, 2015 ... vaccine and immunotherapy company, today announced that the ... application for Fast Track designation and Phase I ... in conjunction with the mutual co-development agreement signed ... obtained Fast Track designation for the DPX-Survivac. , ...
(Date:2/27/2015)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... announced that it will be presenting at CALBIO 2015 ... nd at 3pm PST. Patrick Lucy, chief business officer ... current state of the biosimilar industry landscape entitled ... For more information on CALBIO 2015 and The ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
... 2011 Reportlinker.com announces that a new ... catalogue: Enzymes: Sustainable Alternatives ... http://www.reportlinker.com/p0501016/Enzymes-Sustainable-Alternatives-with-Remarkable-Scope.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical Enzymes are among ... a whole host of different roles in ...
... four billion years of evolution, plants and animals grew ... new comparison of proteins shared across species finds that ... may have actually launched the long journey from microbe ... , suggests that the random introduction of errors into ...
... May 18, 2011 Biomerix Corporation and Cellon today ... 3D Scaffold , a novel three-dimensional tissue scaffold. Under ... 3D Scaffold to research institutions across Europe. ... polyurethane , the Biomerix 3D Scaffold is designed to ...
Cached Biology Technology:Reportlinker Adds Enzymes: Sustainable Alternatives with Remarkable Scope 2Reportlinker Adds Enzymes: Sustainable Alternatives with Remarkable Scope 3Errors in protein structure sparked evolution of biological complexity 2Errors in protein structure sparked evolution of biological complexity 3Biomerix Corporation Reaches European Distribution Agreement with Cellon S.A. 2
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces the ... as part of its 2015 marketing and branding initiatives ... new consumer website for Wocketwallet.com earlier this month. ... said, "Our new corporate website naturally showcases our premiere ...
(Date:2/5/2015)... , Jan. 28, 2015 Research and ... the addition of the "Global Biometrics Market ... Regions and Countries " report to their offering. ... Asia-Pacific is anticipated to ... 2015, owing to increasing government spending towards IT ...
(Date:1/22/2015)... S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its ... of Washington,s Department of Licensing, in the United ... system for driver,s licenses and identification cards to its subsidiary, ... will start in January 2015, with enrollment and card production ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... University of Utah biology Professor Nalini Nadkarni is being ... the American Association for the Advancement of Science (AAAS) ... Award. The AAAS has issued the news release below: ... (AAAS) has named Nalini M. Nadkarni as the recipient ...
... A team of scientists, led by researchers at ... and Zacharon Pharmaceuticals, have developed a simple, reliable test ... inherited metabolic disorders that are currently diagnosed in patients ... possibly irreversible. The findings will be published online ...
... 8, 2012) The anxiety and behavioral issues associated with excess ... and Oprm 1 [mu-opioid receptor MOR 1]), which may point the ... the protein, said Baylor College of Medicine scientists in ... Genetics . Much of the work was done ...
Cached Biology News:Utah biologist wins 2011 AAAS Public Engagement with Science Award 2Utah biologist wins 2011 AAAS Public Engagement with Science Award 3New test spots early signs of inherited metabolic disorders 22 genes affect anxiety, behavior in mice with too much MeCP2 2
Neuropilin-2 Purified Anti-Rat clone 54, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
The product contains 2 ml Dynabeads® Epoxy (4.5 μm). Supplied at 4 x 10e8 beads/ml...
CBF-B (G-2)...
... polyclonal to Endothelin B Receptor Like ... Receptor-Like Protein 2 (ETBR-LP-2) has been ... been isolated from human brain and ... Synthetic peptide (unfortunately, the amino acid ...
Biology Products: